COR388

DRUG2 trials

Sponsors

Cortexyme Inc.

Conditions

Alzheimer DiseaseHealthy Subjects

Phase 1

Study of COR388 HCl in Healthy Subjects

CompletedNCT03331900

Cortexyme Inc.Healthy Subjects

Start: 2017-12-11End: 2018-04-02Updated: 2018-04-18

A Multiple Ascending Dose Study of COR388

CompletedNCT03418688

Cortexyme Inc.Alzheimer Disease

Start: 2018-03-06End: 2018-10-15Updated: 2018-11-07

Related Papers

P4‐542: UTILITY OF SPEECH‐BASED DIGITAL BIOMARKERS FOR EVALUATING DISEASE PROGRESSION IN CLINICAL TRIALS OF ALZHEIMER'S DISEASE

Alzheimer s & Dementia2019-07-014 citations